- Home
- MASI vs ROIV Comparison
MASI vs ROIV Comparison
Compare MASI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASI
- ROIV
- Stock Information
- Founded
- MASI 1989
- ROIV 2014
- Country
- MASI United States
- ROIV United Kingdom
- Employees
- MASI N/A
- ROIV N/A
- Industry
- MASI Medical/Dental Instruments
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- MASI Health Care
- ROIV Health Care
- Exchange
- MASI Nasdaq
- ROIV Nasdaq
- Market Cap
- MASI 9.0B
- ROIV 8.4B
- IPO Year
- MASI 2007
- ROIV N/A
- Fundamental
- Price
- MASI $165.69
- ROIV $10.42
- Analyst Decision
- MASI Buy
- ROIV Strong Buy
- Analyst Count
- MASI 6
- ROIV 7
- Target Price
- MASI $194.80
- ROIV $18.08
- AVG Volume (30 Days)
- MASI 663.7K
- ROIV 4.7M
- Earning Date
- MASI 05-06-2025
- ROIV 02-10-2025
- Dividend Yield
- MASI N/A
- ROIV N/A
- EPS Growth
- MASI N/A
- ROIV N/A
- EPS
- MASI N/A
- ROIV N/A
- Revenue
- MASI $2,094,400,000.00
- ROIV $122,585,000.00
- Revenue This Year
- MASI N/A
- ROIV N/A
- Revenue Next Year
- MASI $12.61
- ROIV N/A
- P/E Ratio
- MASI N/A
- ROIV N/A
- Revenue Growth
- MASI 2.26
- ROIV 140.04
- 52 Week Low
- MASI $101.61
- ROIV $9.76
- 52 Week High
- MASI $194.88
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- MASI 40.05
- ROIV 43.62
- Support Level
- MASI $162.71
- ROIV $10.39
- Resistance Level
- MASI $171.81
- ROIV $10.81
- Average True Range (ATR)
- MASI 8.08
- ROIV 0.35
- MACD
- MASI -2.24
- ROIV 0.03
- Stochastic Oscillator
- MASI 13.77
- ROIV 52.87
About MASI Masimo Corporation
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.